Avidity Biosciences (RNA) News Today

Avidity Biosciences (NASDAQ:RNA) Reaches New 52-Week High at $47.29

Swiss National Bank raised its holdings in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 20.5% during the first quarter, according to its most recent filing with the SEC. The firm owned 140,800 shares of the biotechnology company's stock after purchasing an additional 24,000 sha

Mirae Asset Global Investments Co. Ltd. decreased its holdings in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 77.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 37,462 shares of the biotechnology

Avidity Biosciences (NASDAQ:RNA) Hits New 52-Week High at $46.62

Concurrent Investment Advisors LLC acquired a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 26,005 shares of the biotechnology company's stoc

Avidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) CEO Sarah Boyce sold 28,000 shares of Avidity Biosciences stock in a transaction on Tuesday, July 9th. The stock was sold at an average price of $39.93, for a total value of $1,118,040.00. Following the completion of the transaction, the chief executive officer now owns 205,043 shares in the company, valued at $8,187,366.99. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Avidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) has been given a consensus recommendation of "Buy" by the seven brokerages that are presently covering the firm, Marketbeat reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 1 year target p

Avidity Biosciences (NASDAQ:RNA) Reaches New 1-Year High at $42.55

Wellington Management Group LLP increased its holdings in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 17.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 291,218 shares of the biotechnology c

Avidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) Director Arthur A. Levin sold 5,000 shares of the company's stock in a transaction on Thursday, June 20th. The stock was sold at an average price of $37.59, for a total value of $187,950.00. Following the transaction, the director now directly owns 14,830 shares in the company, valued at approximately $557,459.70. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Avidity Biosciences (NASDAQ:RNA) Shares Gap Up to $37.61

Avidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) has been given a consensus recommendation of "Buy" by the seven brokerages that are covering the firm, Marketbeat.com reports. Seven research analysts have rated the stock with a buy recommendation. The average 1-year target price among anal

Avidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) Director Arthur A. Levin sold 40,000 shares of Avidity Biosciences stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $35.07, for a total transaction of $1,402,800.00. Following the completion of the sale, the director now owns 213,872 shares of the company's stock, valued at approximately $7,500,491.04. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Avidity Biosciences (NASDAQ:RNA) Sees Strong Trading Volume Following Analyst Upgrade

Avidity Biosciences (NASDAQ:RNA) Stock Price Up 4.2% on Analyst Upgrade

Bank of America lifted their price target on Avidity Biosciences from $40.00 to $45.00 and gave the stock a "buy" rating in a report on Thursday.

Avidity Biosciences (NASDAQ:RNA) Sets New 52-Week High at $37.85

Lighthouse Investment Partners LLC bought a new position in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 65,362 shares of the biotechnology company's stock, valued

Needham & Company LLC restated a "buy" rating and set a $35.00 price target on shares of Avidity Biosciences in a report on Monday.

Rafferty Asset Management LLC cut its stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 30.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 270,159 shares of the biotechnology

Avidity Biosciences (NASDAQ:RNA) Stock Price Up 3.2%

Steward Partners Investment Advisory LLC lifted its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 202.6% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 59,000 shares of the biotechnology compa

Avidity Biosciences (NASDAQ:RNA) Shares Down 5.7% After Insider Selling

Charles Schwab Investment Management Inc. boosted its holdings in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 6.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 545,771 shares of the biotechnolog

Trexquant Investment LP trimmed its holdings in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 56.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 69,874 shares of the biotechno

Artisan Partners Limited Partnership decreased its holdings in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 2.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,103,022 shares of the biotechnology company's s

Avidity Biosciences (NASDAQ:RNA) Stock Price Down 4.3%

Dynamic Technology Lab Private Ltd increased its holdings in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 114.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 52,788 shares of the

Avidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) has been given an average recommendation of "Buy" by the six research firms that are currently covering the firm, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month price target